The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

• The company has issued zero common shares since October 2023, marking a decisive break from typical OTC dilution patterns.
• A multi-year share repurchase program has retired more than 20 million shares while authorized shares have been reduced by 60%.
• Earth Science Tech is funding operations and acquisitions through cash flow while legally restricting its future ability to dilute shareholders.

In the microcap market, capital formation is often synonymous with dilution. Companies raise money by issuing new shares, frequently at the expense of long-term shareholders, creating a cycle where growth in operations does not translate into growth in per-share value. Against that backdrop, capital discipline itself becomes a differentiator, and increasingly, a signal of management intent.

Earth Science Tech (OTCID: ETST) has taken an approach that runs counter to long-standing norms in the OTC market. Rather than expanding its share count to fund operations, the company has spent the past two years reversing dilution, tightening its capital structure, and shrinking both its outstanding and authorized shares.

The Inflection Point: October 2023

The most consequential event in Earth Science Tech’s recent capital history is not tied to revenue or an acquisition announcement, but to a single issuance date. According to SEC filings, the last issuance of common stock occurred in October 2023 and was made to an employee. Since that point, the company has issued no additional common shares.

That pause has now extended across multiple reporting periods, including a phase marked by operational expansion and subsidiary integration. During that time, Earth Science Tech funded its activities through operating cash flow rather than equity issuance, effectively halting the incremental share count expansion that characterizes much of the microcap landscape.

From Neutral to Reverse: The Buyback Strategy

In early 2024, the company shifted from simply holding the line on dilution to actively reducing its share count. On January 29, 2024, Earth Science Tech initiated a share repurchase program, signaling a fundamental change in capital allocation priorities.

The program was later expanded by the board in August 2025, increasing the authorized repurchase amount to $10 million and extending the program through December 2027. Public filings confirm that more than 20 million shares have already been repurchased and retired.

This approach creates a structural dynamic that differs meaningfully from typical OTC issuers. While many companies rely on equity issuance to bridge operating gaps, Earth Science Tech has chosen to return capital to shareholders by reducing the public float, allowing operating performance to accrue to a smaller base of outstanding shares.

Reducing the Ceiling, Not Just the Float

Beyond buybacks, Earth Science Tech has taken the less common step of reducing its authorized share count, a move that permanently constrains future dilution.

In 2024, the company amended its Articles of Incorporation to reduce authorized common shares from 750 million to 350 million, eliminating more than half of the potential share supply in a single action. The following year, management further reduced the authorized count to 300 million shares.

This two-stage reduction is notable not only for its scale, but for its implications. Authorized shares represent a company’s maximum potential equity issuance capacity. By lowering that ceiling, Earth Science Tech has legally limited its ability to issue new shares, signaling confidence that future capital needs can be met without relying on equity markets.

Alignment and Ownership Structure

Management ownership further reinforces the capital discipline narrative. Insiders collectively hold approximately 47% of the outstanding shares, representing roughly 138.6 million shares, and filings indicate continued open-market purchases.

This ownership concentration aligns management incentives with long-term per-share value creation rather than short-term financing flexibility. Combined with the absence of recent dilution, it places Earth Science Tech in a distinct minority among OTC-listed companies.

Operating Platform Overview

Earth Science Tech operates as a strategic holding company with controlling interests across several healthcare-related verticals. Its portfolio includes compounding pharmaceuticals, telemedicine platforms, healthcare services, and real estate development.

Subsidiaries include RxCompoundStore.com, a licensed compounding pharmacy operating across multiple states; telemedicine platforms such as Peaks Curative, DOConsultations, and Las Villas Health Care, which serve both English- and Spanish-speaking patient populations; Mister Meds, a physician-founded pharmacy focused on wellness medicine; and Avenvi, a real estate development firm. The company also holds an 80% interest in MagneChef, a direct-to-consumer brand with proprietary intellectual property.

A Structural Outlier in the OTC Market

Viewed collectively, the numbers tell a clear story. No new shares have been issued since October 2023. Ongoing share repurchases, reducing the float. Authorized shares cut from 750 million to 300 million. Significant insider ownership.

In a market where dilution is often assumed, Earth Science Tech has instead engineered structural scarcity in its equity. Whether that approach translates into long-term shareholder value will ultimately depend on operational execution, but from a capital structure standpoint, the company has already distinguished itself by doing what few OTC issuers attempt, and even fewer sustain.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://nnw.fm/ETST

About NetworkNewsWire